SCHEMBL1058173

SCHEMBL1058173

Nc1nc(Cl)c2c(n1)N(Cc1cccnc1)C(=O)C2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRAP1 Q12931 9/20 0.64
HSP90B1 P14625 7/20 0.64
HSP90AA1 P07900 5/20 0.58
LMNA P02545 3/20 0.45
MAPK1 P28482 2/20 0.45
HTT P42858 2/20 0.45
MAPT P10636 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
MEN1 O00255 1/20 0.45
TP53 P04637 1/20 0.45
GAA P10253 1/20 0.45
THRB P10828 1/20 0.45
ALOX15 P16050 1/20 0.45
RECQL P46063 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.43
UBE2N P61088 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1059577 0.77 TRAP1 (0.59) TRAP1HSP90B1HSP90AA1LMNAALDH1A1
SCHEMBL27811666 0.76 ALDH1A1 (0.38) TRAP1HSP90B1LMNAHTTMAPT
SCHEMBL24500020 0.73 TLR7 (0.46) MAPK1TSHR
SCHEMBL1060933 0.72 HSP90AA1 (0.56) TRAP1HSP90B1HSP90AA1
SCHEMBL1057826 0.72 TRAP1 (0.59) TRAP1HSP90B1HSP90AA1HTTMAPT
SCHEMBL3391877 0.72 TRAP1 (0.69) TRAP1HSP90B1HSP90AA1
SCHEMBL1053982 0.71 TRAP1 (0.55) TRAP1HSP90B1HSP90AA1LMNAHTT
SCHEMBL12614221 0.71 TRAP1 (0.66) TRAP1HSP90B1HSP90AA1HTTMAPT
SCHEMBL1059740 0.71 TRAP1 (0.66) TRAP1HSP90B1HSP90AA1HTTMAPT
SCHEMBL1079346 0.71 HSP90AA1 (0.60) TRAP1HSP90B1HSP90AA1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110124634-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. 2011-05-26 US disclosed
US-20110124634-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. 2011-05-26 US disclosed
US-20110124634-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. 2011-05-26 US disclosed
EP-2273882-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES Poniard Pharmaceuticals, Inc. (US) 2011-01-19 EP disclosed
WO-2009139834-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed
WO-2009139834-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PONIARD PHARMACEUTICALS, INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124634-A1 BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES PARK7, BDNF, BACE1 TRAP1 443/4885HSP90B1 1036/4885HSP90AA1 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.